MX2022009962A - Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. - Google Patents
Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.Info
- Publication number
- MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A
- Authority
- MX
- Mexico
- Prior art keywords
- cov2
- sars
- vaccines
- induce
- immune response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976913P | 2020-02-14 | 2020-02-14 | |
| US202062977402P | 2020-02-16 | 2020-02-16 | |
| US202062992710P | 2020-03-20 | 2020-03-20 | |
| US202063026580P | 2020-05-18 | 2020-05-18 | |
| PCT/US2021/018033 WO2021163622A1 (en) | 2020-02-14 | 2021-02-12 | Vaccines and uses thereof to induce an immune response to sars-cov2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009962A true MX2022009962A (es) | 2022-11-09 |
Family
ID=77292751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009962A MX2022009962A (es) | 2020-02-14 | 2021-02-12 | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12577589B2 (https=) |
| EP (1) | EP4103231A4 (https=) |
| JP (1) | JP2023513611A (https=) |
| KR (1) | KR20220154114A (https=) |
| CN (1) | CN115529817A (https=) |
| AU (1) | AU2021220991A1 (https=) |
| BR (1) | BR112022014884A2 (https=) |
| CA (1) | CA3167052A1 (https=) |
| IL (1) | IL295482A (https=) |
| MX (1) | MX2022009962A (https=) |
| TW (1) | TW202140794A (https=) |
| WO (1) | WO2021163622A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220273790A1 (en) * | 2019-06-18 | 2022-09-01 | Citranvi Biosciences, Llc | Rationally engineered carrier proteins for vaccines |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US20240269261A1 (en) * | 2020-03-04 | 2024-08-15 | Premas Biotech Pvt. Ltd | Expression of sars-cov proteins, nucleic acid constructs, virus like proteins (vlps) and methods relevant thereto |
| EP4132576A1 (en) * | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| JP7788403B2 (ja) | 2020-05-17 | 2025-12-18 | シティ・オブ・ホープ | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| CA3181431A1 (en) * | 2020-06-10 | 2021-12-16 | Jurgen Hausmann | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| WO2022025298A1 (ja) * | 2020-07-31 | 2022-02-03 | 公益財団法人東京都医学総合研究所 | 組換えワクシニアウイルス |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| US20230002780A1 (en) * | 2021-06-25 | 2023-01-05 | Applied Biotechnology Institute, Inc. | EXPRESSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE PROTEIN SEQUENCES IN PLANTS AND PLANT PRODUCED VACCINE FOR SAME |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| KR20230031756A (ko) * | 2021-08-27 | 2023-03-07 | 한국과학기술원 | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 |
| US20250228926A1 (en) * | 2021-10-07 | 2025-07-17 | Global Life Sciences Solutions Canada Ulc | Rna vaccine lipid nanoparticles |
| WO2023069461A2 (en) * | 2021-10-19 | 2023-04-27 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
| WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
| WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| GB2624391A (en) * | 2022-11-15 | 2024-05-22 | Univ Cape Town | Recombinant LSDV vectored bovine coronavirus antigen constructs |
| WO2024118079A1 (en) * | 2022-12-01 | 2024-06-06 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
| WO2024206243A1 (en) * | 2023-03-24 | 2024-10-03 | Geovax. Inc. | Pan-betacoronavirus vaccines and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787901A (fr) | 1971-09-11 | 1972-12-18 | Freistaat Bayern Represente Pa | Vaccin antivariolique |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| EP1380651A2 (en) | 1991-08-26 | 2004-01-14 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
| AU5679394A (en) | 1992-11-25 | 1994-06-22 | International Biotechnology Laboratories, Inc. | Hepatitis b virus vaccines |
| EP0942747A1 (en) | 1996-08-26 | 1999-09-22 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| AUPP380598A0 (en) | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
| JP4554887B2 (ja) | 2001-03-08 | 2010-09-29 | アメリカ合衆国 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
| US7025970B2 (en) | 2002-03-15 | 2006-04-11 | Baxter International Inc. | Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods |
| CN102703393A (zh) | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004048582A2 (en) | 2002-11-25 | 2004-06-10 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ati promoters |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| WO2005016238A2 (en) | 2003-05-08 | 2005-02-24 | Duke University | Severe acute respiratory syndrome |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| JP4750024B2 (ja) | 2003-06-20 | 2011-08-17 | プロテイン サイエンシーズ コーポレイション | Ｓａｒｓの免疫原を発現するベクター、そのようなベクター又はその発現産物を含有する組成物、並びにその作製及び使用の方法及びアッセイ |
| CN1918288A (zh) * | 2003-06-20 | 2007-02-21 | 蛋白质科学公司 | 表达sars免疫原的载体、含所述载体或其表达产物的组合物、制备和使用方法和实验 |
| WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| WO2006071250A2 (en) | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| WO2005120565A2 (en) * | 2004-06-02 | 2005-12-22 | New York Blood Center | Sars vaccines and methods to produce highly potent antibodies |
| WO2006022215A1 (ja) * | 2004-08-23 | 2006-03-02 | The Japan Health Sciences Foundation | SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用 |
| US9453239B2 (en) | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
| DK3312272T3 (da) * | 2004-10-08 | 2019-12-02 | Us Gov Health & Human Services | Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner |
| CN100479858C (zh) * | 2005-01-27 | 2009-04-22 | 中国医学科学院实验动物研究所 | 一种重组痘苗-sars疫苗及其制备方法 |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| AU2009319979B2 (en) | 2008-11-03 | 2016-10-20 | Takeda Vaccines, Inc. | Improved methods for isolating enveloped virus-based VLPs free of infectious agents |
| AP2012006258A0 (en) | 2009-10-13 | 2012-06-30 | Geovax Inc | Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| CA2790426A1 (en) | 2010-02-18 | 2011-08-25 | Emory University | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response |
| TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
| US20130280215A1 (en) | 2011-10-18 | 2013-10-24 | Geovax, Inc. | Mva vectors expressing polypeptides and having high level production in certain cell lines |
| US20150140068A1 (en) | 2012-07-06 | 2015-05-21 | Novartis Ag | Immunogenic compositions and uses thereof |
| WO2015009946A1 (en) | 2013-07-17 | 2015-01-22 | Emory University | Method of increasing immune response to hiv antigens |
| WO2015066715A1 (en) | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
| JP2017515841A (ja) | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| EP3188752A2 (en) | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| WO2016068919A1 (en) | 2014-10-29 | 2016-05-06 | Geovax, Inc. | Combination therapy for treating viral reservoirs |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| EP3402802B1 (en) | 2016-01-08 | 2023-04-12 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| PL3402888T3 (pl) * | 2016-01-12 | 2021-04-19 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Środki i sposoby leczenia hbv |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| AU2017221379A1 (en) | 2016-02-16 | 2018-08-16 | Geovax Inc. | Multivalent HIV vaccine boost compositions and methods of use |
| EP3463448A4 (en) * | 2016-05-30 | 2020-03-11 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
| EP4599847A3 (en) | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| MA47790A (fr) * | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018195447A1 (en) | 2017-04-20 | 2018-10-25 | Geovax Labs, Inc. | Recombinant mva-based hiv immunogens and uses thereof |
| WO2019018501A1 (en) | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| US20210220469A1 (en) | 2017-08-25 | 2021-07-22 | Geovax, Inc. | Immuno-Oncology Compositions and Methods for Use Thereof |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2020247547A1 (en) | 2019-06-03 | 2020-12-10 | Geovax, Inc. | Cancer vaccine compositions and methods for use thereof |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| KR20220148823A (ko) | 2020-02-03 | 2022-11-07 | 시티 오브 호프 | 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도 |
| MX2022009836A (es) | 2020-02-11 | 2022-11-30 | Us Health | Vacuna para sars-cov-2. |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| US20210260182A1 (en) * | 2020-02-26 | 2021-08-26 | Scott J. Goebel | RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS |
| CR20220501A (es) | 2020-03-13 | 2023-01-23 | Oxford Univ Innovation Limite | Composiciones y métodos para la inducción de una respuesta inmune |
| IL296617A (en) | 2020-03-20 | 2022-11-01 | Biontech Us Inc | Vaccines against the corona virus and methods of use |
| US20240210415A1 (en) | 2020-03-24 | 2024-06-27 | Icahn School Of Medicine At Mount Sinai | Recombinant sars-cov-2 spike protein and uses thereof |
| TW202203966A (zh) | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| US20240285751A1 (en) | 2020-04-01 | 2024-08-29 | Diosynvax Ltd | Coronavirus vaccines |
| WO2021216743A2 (en) | 2020-04-21 | 2021-10-28 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| JP7788403B2 (ja) | 2020-05-17 | 2025-12-18 | シティ・オブ・ホープ | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| EP3928789A1 (en) * | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| MX2023009008A (es) | 2021-02-02 | 2023-10-05 | Geovax Inc | Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación. |
-
2021
- 2021-02-12 JP JP2022549163A patent/JP2023513611A/ja active Pending
- 2021-02-12 BR BR112022014884A patent/BR112022014884A2/pt unknown
- 2021-02-12 CN CN202180015836.7A patent/CN115529817A/zh active Pending
- 2021-02-12 CA CA3167052A patent/CA3167052A1/en active Pending
- 2021-02-12 WO PCT/US2021/018033 patent/WO2021163622A1/en not_active Ceased
- 2021-02-12 KR KR1020227031509A patent/KR20220154114A/ko active Pending
- 2021-02-12 AU AU2021220991A patent/AU2021220991A1/en active Pending
- 2021-02-12 EP EP21754084.8A patent/EP4103231A4/en active Pending
- 2021-02-12 IL IL295482A patent/IL295482A/en unknown
- 2021-02-12 MX MX2022009962A patent/MX2022009962A/es unknown
- 2021-02-17 TW TW110105390A patent/TW202140794A/zh unknown
-
2022
- 2022-08-15 US US17/888,131 patent/US12577589B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513611A (ja) | 2023-03-31 |
| CA3167052A1 (en) | 2021-08-19 |
| IL295482A (en) | 2022-10-01 |
| AU2021220991A1 (en) | 2022-09-29 |
| KR20220154114A (ko) | 2022-11-21 |
| CN115529817A (zh) | 2022-12-27 |
| TW202140794A (zh) | 2021-11-01 |
| EP4103231A1 (en) | 2022-12-21 |
| US12577589B2 (en) | 2026-03-17 |
| WO2021163622A1 (en) | 2021-08-19 |
| BR112022014884A2 (pt) | 2022-10-11 |
| US20220396810A1 (en) | 2022-12-15 |
| EP4103231A4 (en) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009962A (es) | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. | |
| MX2021003175A (es) | Vacuna contra el virus de la peste porcina africana. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
| JP2016510989A5 (https=) | ||
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| AU2009303788B2 (en) | Smallpox DNA vaccine and the antigens therein that elicit an immune response | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| CA3067405A1 (en) | Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides | |
| MX2017016273A (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. | |
| AR124928A2 (es) | Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| NZ598605A (en) | Vaccine against african horse sickness virus | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2017503479A5 (https=) | ||
| WO2005046621A3 (en) | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines | |
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| WO2006073431A3 (en) | Avipox recombinants expressing foot and mouth disease virus genes | |
| MX390966B (es) | Vacunas contra el dengue | |
| RU2017132190A (ru) | Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними | |
| US20090053256A1 (en) | Poxvirus Methods And Compositions | |
| JP2021528367A5 (https=) | ||
| ZA202309287B (en) | Coronavirus vaccine comprising a mosaic protein | |
| WO2008127307A3 (en) | Induction of an immune response against dengue virus using prime-boost approach |